Pure Global
NCT06286189

Trazodone on OSA Endotypes

Effect of Trazodone on Obstructive Sleep Apnea Endotypes and Severity
Brigham and Women's Hospital·Phase 1/2·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Obstructive Sleep Apnea
Drug/Device/Intervention
Placebo oral tablet
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Brigham and Women's Hospital
Location
Boston, United States of America
Timeline & enrollment
Phase
Phase 1/2
Start date
Jan 01, 2024
End date
Jun 01, 2025
Enrollment
18 participants
Primary outcome

Effect of trazodone on arousal threshold (%eupnea)

Summary

Obstructive sleep apnea (OSA) is common and has major health implications but treatment
 options are limited. Some OSA patients with low arousal threshold wake up prematurely during
 an obstructive event and do not have time for spontaneous upper airway (UA) dilator muscle
 recruitment. As a consequence they are exposed to apnea and hypopnea cycling. In this
 protocol the investigators will test the effect of trazodone administered before sleep on OSA
 traits and OSA severity during sleep.

ICD-10 classifications
Sleep apnoeaSleep disordersSleep disorder, unspecifiedPrimary sleep apnoea of newbornNonorganic sleep disorders
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06286189
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06286189 through Pure Global AI's free database. This Phase 1/2 trial is sponsored by Brigham and Women's Hospital and is currently Recruiting. The study focuses on Obstructive Sleep Apnea. Target enrollment is 18 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.